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ABSTRACT

Objectives: To determine the association between the presence of V4 polymorphisms of the ADAM33
gene and asthma disease and to describe the frequency of T1 polymorphism in patients from a hospital
in the Lambayeque region. Method: Design of cases and controls. Location: Hospital Almanzor Aguinaga
Asenjo - EsSalud, level of complexity III-1. Population: patients between 5-17 years old attended by an
outpatient clinic. The cases were patients diagnosed according to the Global Initiative for Asthma (GINA)
2016 guidelines. Controls were patients without a diagnosis of any chronic lung disease or a family history
of asthma. Results: In most cases, both cases and controls did not present the V4 polymorphism, I feel
positive only in 46% of cases and 31% of controls. When the association between the V4 polymorphism
and the presence of asthma was evaluated, the OR was 1.93 (95% CI: 0.62 - 6.00), with a non-significant
value (p = 0.196) for the Xi test --Pearson square. However, the T1 polymorphism was present in 87% of
cases; and the proportion of Tumbesinos with the mutation was much lower than that of other regions.
Conclusions: No association was found between the V4 polymorphism and the presence of asthma in
patients from a Lambayeque hospital. The T1 polymorphism occurs quite frequently in asthmatic patients
at Hospital Almanzor Aguinaga Asenjo - ESSalud.
Key words: Asthma; SNPs; ADAM proteins (source: MeSH NLM).

RESUMEN

Objetivos: Determinar asociación entre la presencia de los polimorfismos V4 del gen ADAM33 y la
enfermedad del asma y describir la frecuencia del polimorfismo T1 en pacientes de un hospital de la
región Lambayeque. Métodos: Diseño de casos y controles. Escenario: Hospital Almanzor Aguinaga
Asenjo – EsSalud, nivel de complejidad III-1. Población: pacientes entre 5-17 años atendidos por consultorio
externo. Los casos fueron los pacientes diagnosticados según las directrices de Global Initiative for
Asthma (GINA) 2016. Los controles fueron pacientes sin diagnóstico de alguna enfermedad pulmonar
crónica ni antecedentes familiares de asma. Resultados: En su mayoría tanto casos como controles no
presentaron el polimorfismo V4, siento positivo solo en el 46% de los casos y 31% de los controles. Cuando
se evaluó la asociación entre el polimorfismo V4 y la presencia de asma, el OR fue de 1,93 (IC95%: 0,62 –
6,00), con un valor no significativo (p = 0,196) para la prueba de Xi-cuadrado de Pearson. Sin embargo, el
polimorfismo T1 estuvo presente en el 87% de casos; y la proporción de tumbesinos con la mutación fue
mucho más baja que la de otras regiones. Conclusión: No se encontró asociación entre el polimorfimo
V4 y la presencia de asma en pacientes de un hospital de Lambayeque. El polimorfismo T1 se presenta
con bastante frecuencia en los pacientes asmáticos del hospital Hospital Almanzor Aguinaga Asenjo –
ESSalud.
Palabras clave: Asma; polimorfismo genético y en ADAM33 (fuente: DeCS BIREME).
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Asthma is the most common chronic disease among
children(1,2).Worldwide, in children, it has increased
200% in the last 20 years(3) In Latin America, Peru is in
the intermediate prevalences group with 21.47%(4)
A study of children in Ica, found a prevalence of
13.5% of this disease, predominating children under
5 years (39%)(5) In Chiclayo province , department
of Lambayeque, in 2017, it was reported 622 cases
of asthma, with 52% being children under 11 years
of age and for 2018 the Almanzor Aguinaga Asenjo
Hospital reported 331 cases of allergic asthma(6).
The incidence of asthma increases as communities
adopt Western lifestyle and urbanize(7). Although
there are many triggering risk factors such as
exposure to aeroallergens 8 and viral infections,
what finally generate this disease is the idiosyncrasy
of the population with environmental ang genetic
factors(3,9-11).
Numerous studies
have shown that the V4
polymorphism in the ADAM33 gene is significantly
related to susceptibility to asthma(1,4,12–16), as well as
with the accelerated decrease in forced expiratory
volume in the first second (FEV1) in spirometry(17,18);
however, these associations change depending on
ethnic group 19 For instance, in Shanghai and Shandog
(China) it was shown that in Caucasian and Asian
populations the V4 polymorphism was associated
with asthma, Furthermore, in the subgroups analysis
by source of controls, significant associations were
found between this polymorphism and the risk of
asthma in population and hospital subgroups(14,20)
Likewise, in the Uyghur population (China) it was
demonstrated that polymorphisms T2 (AG + AA) and
V4 (CG + GG) contributed to a greater susceptibility
to Asthma(18). In northeastern Iran, Kamiri M., found
associations between polymorphisms of the C
allele of T1 with severe asthmatic patients and the
G allele of nucleotide V4 with moderate asthmatics,
respectively (p = 0.006, p = 0.01)(8) and in the study
by Foley SC conducted in Canada, the expression of
ADAM33 mRNA was significantly higher in moderate
and severe asthma compared to mild asthma (p
<0.05) and controls(21) In Indian population it was
found that polymorphisms in F + 1, ST + 4, V4 and
mutant alleles were significantly associated with
an increased risk of asthma (p = 0.031 - <0.001)(22).
In Caracas (Venezuela) it was concluded that the V4
polymorphism is associated with asthma, the G / G
genotype being associated with an increased risk
of presenting it and C / C with a decreased risk(13).
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However, in Asian and Latin American populations
the results are contradictory(1,15,23–26), in a metaanalysis about polymorphisms of a Disintegrin
and metalloprotease 33 gene (ADAM33) and
the risk of asthma, significant relationships were
reported between asthma and T1, V4, F + 1 and T
+ 1 polymorphisms in the general population, and
in the case of the subgroups analysis by ethnicity,
a positive result was only found for polymorphisms
T1, V4, F + 1 and T2 in Asia, but no such associations
were found in Europe or Latin America, concluding
that polymorphisms T1, V4, F + 1, T2 and T + 1
in the ADAM33 gene are risk factors for asthma,
especially in the Asian population(15), although Zhu
SF demonstrated absence of association for the
polymorphism of the ADAM33 gene in Mongolian
population(25). Regarding the Latin American
population, Denise L concluded that the ADAM33
gene is not an important risk factor for asthma or for
the phenotypes associated with asthma in Mexicans
or Puerto Ricans(26). In Colombia, Vergara et al. they
found no association between the presence of
asthma and the polymorphisms of alleles, genotypes
and haplotypes of ADAM33; and they did not find an
association in the subcategories of severe, moderate,
or mild asthmatic patients compared to control(23).
Thus, to date, polymorphisms of the ADAM33 gene
have been associated with the presence of asthma in
Caucasian, African, Hispanic and Asian populations;
however, this information is scarce in the mestizo
population and non-existent in the Peruvian
population.
Considering that the Peruvian population has great
ethnic wealth, in addition to the high prevalence
present in the country and the continuous increase
in this trend, it is interesting to explore this
association. Therefore, the objective of the study was
to determine the association between the presence
of the V4 polymorphism of the ADAM33 gene and
asthma, and to describe the T1 polymorphism in
patients from a hospital in Lambayeque region.

METHODS
Population and sample
A case-control study was developed for the V4
polymorphism, and a descriptive cross-sectional one
for the T1. Two groups were compared in the age
range between 5-17 years attended by an medical
outpatient office of the Almanzor Aguinaga AsenjoESSalud Hospital (Hospital III-1) of the Lambayeque
department, during the year 2019.
2
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Two groups were compared in the age range
between 5-17 years attended by an medical
outpatient office of the Almanzor Aguinaga AsenjoESSalud Hospital (Hospital III-1) of the Lambayeque
department , during the year 2019: the cases
were patients diagnosed according to the 2016
Global Initiative for Asthma (GINA) guidelines and
those with absence of symptoms due to the use
of anti-asthma medications, likewise, patients
with asthmatic attacks were excluded; the control
subjects did not have a diagnosis of any chronic lung
disease or a family history of asthma. In both groups,
those buccal swab samples which were no longer
viable were excluded.

Sample collection and clinical parameters
Once the consultation was over, the oral swab was
performed in the same office, through the invitation
made by a pediatric pulmonologist. The buccal cell
sample was obtained from the buccal swab with a
sterile swab, which was then stored in a sterile 15mL
screw cap tube containing 2mL of physiological

Through a data collection sheet, patients' general
data such as age, sex, origin, duration of the
disease, and asthma control were obtained, which
was obtained by applying a survey recommended
by the GINA that consisted of four questions. The
average time for taking the sample and filling in the
questionnaire was 10 minutes.

Genomic DNA extraction and genotyping
Genomic DNA was obtained using the PROMEGA
Extraction Kit, following the instructions
recommended by the manufacturer. The
polymorphisms T1 (rs2280091) and V4 (rs2787094)
of the ADAM33 gene were determined by PCR.
The amplification mix for a final reaction volume
of 20 µl contained 20 ng of genomic DNA and
a final concentration of 2.5 µM of magnesium
chloride, 200 µM of DNTPs and 1 µM of each
primer. The thermal cycler (Biorad, USA) was used
under the following temperature conditions: initial
denaturation at 95 ° C for 5 minutes, cycles of
95 ° C for 30 seconds, hybridization at 65 ° for 30
seconds and extension at 72 ° for 30 seconds, a final
extension of 72 ° for 5 minutes was carried out to
later store the amplification products at 4 ° C until
their electrophoresis (Table 1). Electrophoresis was
carried out in 2% polyacrylamide.

ORIGINAL PAPER

A simple random sampling was carried out to obtain
the cases and controls (V4), and a census study for T1.
To estimate the sample size, 23 cases and 23 controls
were calculated for the V4 polymorphism, with 6,375
as the expected OR(25); and for the T1 polymorphism,
the sample consisted of all those asthmatic patients
who agreed to participate. It was calculated with the
OpenEpi software, using a confidence level of 95%, a
power of 80%, a ratio of controls per case of 1. Each
participant signed an informed consent and assent,
and the study was in accordance with the ethical
principles of research in human beings consigned
in the Declaration of Helsinki and Resolution 8430 of
1993 of the Ministry of Health of Peru. In addition, the
study had the approval of the Bioethics Committee
of the Faculty of Medicine of the Universidad Católica
Santo Toribio de Mogrovejo with Resolution No.
593-2018-USAT-FMED and the Almanzor Aguinaga
Asenjo Hospital Ethics Committee.

serum. The samples were transported in a cooler
with a cold chain to the Research Laboratory of
Universidad Católica Santo Toribio de Mogrovejo,
where they were refrigerated until processing.

RFLP technique
The amplification products of the T1 genes with
374bp and V4 of 400bp were cut with the Ncol
enzymes and Pst1, respectively, the incubation time
was 37 ° for 15 hours for the two enzymes in a final
volume of 37 ul. Restriction products were observed
on 2% polyacrylamide gel and visualized with UV
transilluminator.

Table 1. PCR primers and programs for genotyping ADAM33 by PCR-RFLP.
SNP ID

Gen/SNP primer

Sequence

PCR program

Rs2787094

ADAM33 V4C/G F
ADAM33 V4C/G R

5’-ACACACAGAATGGGGGAGAG-3’
5’-CCAGAAGCAAAGGTCACACA-3’

94°C 5 min; 35 ciclos, 94°C 30s,
53°C 30 s, 72°C 30 s; 72°C 5 min

Rs2280091

ADAM33 T1A/G F
ADAM33 T1A/G R

5’-ACTCAAGGTGACTGGGTGCT-3’
5’-GAGGGCATGAGGCTCACTTG-3’

94°C 5min; 35 ciclos, 94°C 30s,
54°C 30s, 72°C 30 s; 72°C 5 min
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Table 2. Restriction enzymes and length of the digested fragments.

Restriction enzyme

V4C/G

T1A/G

Pstl
G: 168+206
C: 374

Ncol
A:140+260
G:400

Statistic analysis

ORIGINAL PAPER

Measures of central tendency, especially medians,
and of dispersion were calculated to describe the
quantitative variables. The qualitative variables were
expressed with absolute and relative frequencies.
To determine the association between the V4
polymorphism and the presence of asthma, the

Pearson Xi-square test was used, and the OR was
subsequently calculated.
The T1 polymorphism was described with absolute
and relative frequencies. For all tests a confidence
level of 95% was used, and a significance level of 5%
or 0.05. SPSS version 25.0 (IBM, New York) software
was used for all statistical analyzes.

Table 3. Demographic and clinical characteristics of cases and controls.
Cases V4
n (%)

Controls V4
n (%)

P-value

Cases&
(T1)

17 (65)

13 (50)

-

15 (40)

9

13 (50)

-

23 (60

8; 5-10,3

9; 7-11,3

-

9,5; 7-11,3

Lambayeque

18 (70)

21 (81)

-

20 (53)

Tumbes

4 (15)

2 (7,5)

-

12 (32)

Cajamarca

2 (7,5)

1 (4)

-

2 (5)

Others

2 (7,5)

2 (7,5)

-

4 (10)

3; 2 – 6,3

-

-

3; 1 – 5,3

1 – 5 years

17 (65)

-

-

26 (69)

> 5 years

7 (27)

-

-

9 (24)

< 1 year

2 (8)

-

-

3 (7)

Partially controlled

14 (54)

-

-

17 (45)

Well controlled

8 (31)

-

-

16 (42)

Not controlled

4 (15)

-

-

5 (13)

Negative

14 (54%)

18 (69%)

-

-

Positive

12 (46%)

8 (31%)

-

-

Negative

-

-

-

5 (13)

Positive

-

-

-

33 (87)

Variable
Sex
Male
Female
Age (Med; IQR)
Origin

Sick time (Med; RI)
Categorized sick time

Asthma control

V4

T1

* n = 26 children. Med = median. IQR = interquartile range. & = 38 patients.
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RESULTS

polymorphism cases was 3 years (IQR: 2 - 6.3 and IQR:
1 - 5.3 years), respectively; Likewise, more than half in
both groups (65 and 69% for V4 and T1) had a time of
illness that ranged from 1 to 5 years.

Regarding the sociodemographic variables, the
global median age was 9 years (IQR: 6 - 11 years), the
V4 cases had a median age of 8 (IQR: 5 - 10.3) and the
V4 controls had a median 9 years old (IQR: 7 - 11.3).
The proportion of male cases was 65% and 40% for
V4 and T1, respectively; while in the controls the
proportion of men and women was similar (50%).

Respect to the origin, both groups came mostly from
Lambayeque. With respect to the V4 polymorphism,
in most cases both cases and controls did not present
the polymorphism, I feel positive only in 46% of
the cases and 31% of the controls. However, the T1
polymorphism was present in 87% of cases.

54% of patients with V4 polymorphism had
partially controlled asthma, while patients with T1
polymorphism, 45% were partially controlled and
16% well controlled. In both groups only 15 and 13%
were not controlled.

When the association between the V4 polymorphism
and the presence of asthma was evaluated, the OR
was 1.93 (95% CI: 0.62 - 6.00), p value = 0.196 for the
Pearson Xi-square test.

The median time of illness for both the V4 and T1

ORIGINAL PAPER

Table 4. Frequency of V4 polymorphism according to sex
V4

Female

Male

Total

Negative

13

19

32

Positive

9

11

20

Total

22

30

52

No differences were found regarding the proportion
of men and women with the presence of the
mutation. Concerning the total of women, 41%

presented the polymorphism, while of the total of
men, 37% presented it.

Table 5. Frequency of V4 polymorphism according to Asthma Control.
V4

Well controlled

Not controlled

Partially controlled

Total

Negative (C)

6

2

6

32

Positive (G)

2

2

8

20

Total

8

4

14

52

The ratio of cases with the presence and absence of
the factor according to the time of illness remains
close to 1: 1. Considering the classification according
to the type of asthma control, the proportion
of sequences with cytosine and guanine for the

Published by INICIB-URP, 2021

patients classified as “uncontrolled” and “partially
controlled” remained at 1: 1, except for the case of
“well controlled” patients. ”, Whose ratio of patients
with C to G was 3: 1.
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Table 6. Frequency of V4 polymorphism according to origin.
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V4

Amazonas

Cajamarca

Lambayeque

Trujillo

Tumbes

Total

Negative

0

2

23

1

6

32

Positive

1

1

16

1

1

20

Total

1

3

39

2

7

52

The ratio of positive to negative factors was approx. 1:
1, except for Tumbes, where the proportion of native
people with the mutation is much lower than in other
regions. Regarding the total number of patients from
Tumbes, only 14% presented the mutation, while in
Cajamarca it was 33%, and Lambayeque 41%.

FROM T1
From the 37 patients with asthma who were
evaluated for the T1 polymorphism, 87% presented
the polymorphism, and only 5 patients did not
present it, of them, 3 came from Lambayeque, 3 had
well-controlled asthma, 3 were male, and 3 had one
to five years of illness.

DISCUSSION
Genetic variations of ADAM33 can lead to abnormal
changes in smooth muscle cells and fibroblasts, which
results in hyperresponsiveness and remodeling of the
airways, which is correlated with the development of
inflammation in the pathogenesis of Asthma(27).
Using a case-control design, no association of
individual polymorphisms or V4 haplotypes of the
ADAM33 gene was found with the development of
asthma in the pediatric population of the Hospital
Almanzor Aguinaga Asenjo. This contrasts with the
results of many studies, which found that ADAM33
polymorphisms and various haplotypes were
strongly associated with asthma, predominantly
in the Caucasian, Asian and Venezuelan
population(8,13,16,20,21,25,27–29). In the study made by Van
Eerdewegh et al., Patients were stratified based on
the presence of bronchial hyperresponsiveness,
and in the present study, patients were stratified
according to the severity of asthma. The same
restriction enzymes, amplification sequences, among
others, were used respecting a study in a Venezuelan
population, which did find an association with the V4
https://inicib.urp.edu.pe/rfmh/vol21/iss2/5
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polymorphism in the C / C (OR: 0.14) and G / G ( O:
2.10).
Our results suggest that the V4 polymorphism of the
ADAM33 gene would not be an important gene for
asthma or for the severity of asthma in our population.
The genetic basis of asthma may differ between
ethnic groups: a particular subset of polymorphisms
of the ADAM33 gene were identified as risk factors
for asthma in Caucasian ethnic groups in the United
Kingdom and the United States(14), in the same way,
V4 and T1 polymorphisms were identified as risk
factors for asthma in a Venezuelan population(11),
However, this contrasts with the results of a study
carried out in Puerto Rican and Mexican populations
in which no such association was evidenced(26).
According to the authors, this is the first study on
the analysis of the V4 polymorphism in Peruvian
children. Differences in genetic or environmental
risk factors may explain the observed differences(30);
however, a deep research is necessary to cover a
larger population from other regions, for example,
in this study, it was found that asthmatic patients
from the Tumbes region presented a much lower
proportion of mutation than that of other regions,
only 14% compared of Cajamarca and Lambayeque
which was 33% and 41%, respectively.
One ADAM33 variant, the V4 polymorphism, would
be related to the splicing of the gene's mRNA, while
T1 is related to the elimination of a phosphorylation
site important for cell signaling. Modifications in
mRNA stability that affect the amount of enzyme
secreted may be involved with greater cell
turnover and therefore with a greater probability
of developing asthma(13). In a meta-analysis of 29
case-control studies, a general association was
found between T1 and the presence of asthma;
notwithstanding, when analyzed according to
ethnicity, a positive association was found for T1
6
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in the Asian population, but not in the European
or Latin American population - only two cases and
controls from two countries (Brazil and Colombia)
were analyzed 15- This agrees with the absence of
association found for the T1 polymorphism and the
presence of asthma in the Mexican and Puerto Rican
population(26), however, it disagrees with what was
found in the Venezuelan population: in the study by
Martínez, for T1, an association was found between
the presence of the GGAA diploma of ADAM33 (V4
/ T1) and an increased risk of presenting asthma(13).

that it can be determine the association level. These
results are particularly important to Peru due to the
high prevalence of asthma, the high morbidity and
mortality in this population(2,4,6). Identification of
specific ethnic and environmental genetic risk factors
for asthma allows understanding the mechanisms
and developing more effective and specific therapies
for these populations.

CONCLUSION
There is no association between the V4 polymorphism
and the presence of asthma in pediatric patients
from a hospital in Lambayeque; however, T1
polymorphism occurs with high frequency (87%)
in asthmatic patients at the Hospital Almanzor
Aguinaga Asenjo - ESSalud.
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In the present research, it was found that the
frequency of T1 polymorphism was high in asthmatic
patients at the Hospital Almanzor Aguinaga AsenjoESSalud (87%), yet, it is recommended to study the
frequency of said polymorphism also in controls, so
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